We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL
Nuvalent
NUVL
+$5.8M
3
SLNO
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.71B
$4.94M 1.13%
203,739
-22,807
-10% -$389K
AXSM icon
27
Axsome Therapeutics
AXSM
$10.8B
$4.94M 1.13%
20,183
-254
-1% -$55.1K
TVTX icon
28
Travere Therapeutics
TVTX
$6.15B
$4.9M 1.12%
86,233
+49,908
+137% +$2.21M
VERA icon
29
Vera Therapeutics
VERA
$2.59B
$4.54M 1.04%
105,907
+36,666
+53% +$1.37M
NVDA icon
30
NVIDIA
NVDA
$5.56T
$4.36M 0.99%
21,792
-628
-3% -$129K
GHRS icon
31
GH Research
GHRS
$1.94B
$4.27M 0.97%
158,770
-54,442
-26% -$1.14M
PALI icon
32
Palisade Bio
PALI
$364M
$4.24M 0.97%
2,030,927
+11,601
+0.6% +$22.8K
ARGX icon
33
argenx
ARGX
$64.6B
$4.23M 0.96%
4,561
-357
-7% -$295K
MAZE
34
Maze Therapeutics
MAZE
$1.46B
$4.08M 0.93%
136,572
+36,722
+37% +$962K
OCUL icon
35
Ocular Therapeutix
OCUL
$2.34B
$4.01M 0.91%
408,534
-33,039
-7% -$299K
ORKA
36
Oruka Therapeutics
ORKA
$6.13B
$3.99M 0.91%
41,902
-37,009
-47% -$2.47M
DYN icon
37
Dyne Therapeutics
DYN
$4.53B
$3.82M 0.87%
171,961
-10,968
-6% -$204K
EWTX icon
38
Edgewise Therapeutics
EWTX
$4.68B
$3.7M 0.84%
90,996
-935
-1% -$32.2K
MLTX icon
39
MoonLake Immunotherapeutics
MLTX
$1.28B
$3.66M 0.83%
187,946
-6,009
-3% -$109K
INSM icon
40
Insmed
INSM
$27.6B
$3.33M 0.76%
31,256
+6,940
+29% +$840K
CLDX icon
41
Celldex Therapeutics
CLDX
$3.12B
$3.24M 0.74%
86,964
-2,433
-3% -$78.6K
AMZN icon
42
Amazon
AMZN
$2.79T
$3.19M 0.73%
13,397
-9,000
-40% -$2.26M
IVA
43
Inventiva
IVA
$1.13B
$3.14M 0.72%
831,442
+215,776
+35% +$1.04M
TLN
44
Talen Energy Corp
TLN
$15.2B
$3.13M 0.71%
8,148
+5,030
+161% +$1.84M
RLMD icon
45
Relmada Therapeutics
RLMD
$473M
$3.08M 0.7%
+445,799
New +$3.12M
PTGX icon
46
Protagonist Therapeutics
PTGX
$9.43B
$3M 0.68%
24,460
-9,392
-28% -$981K
ERAS icon
47
Erasca
ERAS
$5.66B
$2.94M 0.67%
160,328
-20,741
-11% -$297K
VRDN icon
48
Viridian Therapeutics
VRDN
$2.6B
$2.94M 0.67%
159,885
+25,656
+19% +$413K
HPE icon
49
Hewlett Packard
HPE
$69B
$2.67M 0.61%
59,081
-30,900
-34% -$1.12M
MLYS icon
50
Mineralys Therapeutics
MLYS
$2.49B
$2.32M 0.53%
86,085
+39,307
+84% +$1.08M
1
2
3 4 5

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.